When the brands fail by Singapore Management University
Singapore Management University
Institutional Knowledge at Singapore Management University
Perspectives@SMU Centre for Management Practice
6-2013
When the brands fail
Singapore Management University
Follow this and additional works at: https://ink.library.smu.edu.sg/pers
Part of the Advertising and Promotion Management Commons, and the Marketing Commons
This Journal Article is brought to you for free and open access by the Centre for Management Practice at Institutional Knowledge at Singapore
Management University. It has been accepted for inclusion in Perspectives@SMU by an authorized administrator of Institutional Knowledge at
Singapore Management University. For more information, please email libIR@smu.edu.sg.
Citation
Singapore Management University. When the brands fail. (2013). Perspectives@SMU.
Available at: https://ink.library.smu.edu.sg/pers/275
WHEN BRANDS FAIL 
Published:  
26 Jun 2013 
 
Good branding can help companies, but it can inflict serious damage when things go wrong 
What do Colgate, Nike, and Apple’s iPod have in common beyond being global consumer 
brands? Answer: They all had product recalls due to defects. 
“Colgate had a toothpaste contamination problem, and they had to withdraw the product and 
then re-launch it in the marketplace,” recalls Srinivas Reddy, Professor of Marketing at the Lee 
Kong Chian School of Business at SMU. “One of Nike’s shoes had a metallic clasp in one of their 
(Jordan Trunner) shoes which popped out and cut people. First generation iPod nanos had a 
problem with their batteries – they overheated and leaked.” 
Speaking at the SMU-Brand Finance Asia-Pacific Forum 2013, Reddy explained that these 
instances of brand failure may have hurt sales and company image, but they are relatively minor 
– the products were recalled, fixed, and re-launched with little lasting negative impact. Some 
brands, however, never recover from their crises. 
“Perrier had benzene contamination at source,” Reddy recounts. “They had to withdraw the 
product for almost a year, and competitors rushed to fill the vacuum during the year. They had a 
dominant position in the naturally-aerated water product segment which they never recovered.” 
PRESSURE TO PERFORM 
Perrier’s problems, however, were atypical because they were not the direct consequence of 
choices made by the company i.e. it is a naturally occurring product, not a mechanically or 
electronically manufactured one. 
“Much of the problems that I see in terms of brand failure come from firms doing a tradeoff 
between three things,” Reddy explains. “One: time to market - you want to get to the market fast. 
Two: You want to get the right product to the market - you cannot throw into the marketplace a 
product that is not perfect. Three: The development cost – you have to be on budget.” 
To understand the pressure to deliver products on time and on budget, consider this: Sony’s 
stock price sank 3.6 percent on the day it announced that the PlayStation 3 would not make the 
market on time; the stock price of EADS, Airbus’ parent company, dropped 26 percent overnight 
in 2006 when it announced that the A380 will be delayed, while Boeing's stock gained 6.5 
percent. 
BAD MEDICINE 
Such pressure is especially acute for the pharmaceutical industry, where each day of delay in 
introducing a new drug costs an estimated $1 million. On top of that, the products must be 
perfect because serious injury or death could result otherwise. When that happens, it is what 
Reddy calls a “catastrophic brand failure”, where there is a “fatal outcome from usage of the 
product, and which consequences are non-correctable”. 
Reddy cites the example of the arthritis drug, Vioxx, produced by American pharmaceutical 
company Merck. “At that time, for millions and millions of arthritis sufferers, there was nothing 
that was available which was also safe. The drugs that are usually available are Aspirin and 
other drugs that are not strong enough. And if they are strong enough, they cause other side 
effects, so there was never a way to treat it properly. So when Vioxx came out, people claimed it 
as a miracle drug because, for the first time, arthritis sufferers had a way to get over the pain.” 
The results of Vioxx consumption are now fairly well known: young and otherwise healthy arthritis 
patients died of heart attacks. In 2007 Merck paid $4.85 billion in a class action lawsuit, but 
Reddy estimates that total damage could have been $37 billion after taking into account lost 
profits and loss of market equity. 
That $37 billion includes $2 billion in lost profits due to spillover effects on other drugs produced 
by Vioxx. That damage to Merck’s goodwill could perhaps have been even greater if the 
corporate brand had been more closely associated with the product brand. One needs only to 
look at the packaging of drugs by the big pharmaceutical companies – Johnson & Johnson; 
Pfizer; Roche; GlaxoSmithKline – to notice one thing: the name of the drug is always more visible 
than the corporate brand. 
“If you look at pharmaceutical corporate brands, they never attach their corporate brands too 
closely with the product brands,” Reddy says. “What they have done is try to protect the 
corporate name because they don’t want to have the effect that Baycol had on the rest of Bayer’s 
brands.” 
LESSONS FROM THE BAYCOL DEBACLE 
Baycol was a cholesterol-lowering drug created by Germany’s Bayer. It was withdrawn in 2001 
after causing over 50 deaths from kidney and other organ failures. Five of nine major brands of 
Bayer drugs showed a significant drop in sales, and sales dropped from €6.1 billion in 2000 to 
€4.1 billion in 2005. “Bayer was attached too closely to Baycol just by the name,” Reddy 
explains. 
The biggest beneficiary from Baycol’s demise was Lipitor, produced by Pfizer. As of 2008, it had 
worldwide sales of $12.4 billion, where the benchmark of success for a new drug is $1 billion. 
Pfizer is also the producer of the erectile dysfunction drug, Viagra.  
“It’s not the biggest drug, but it’s the most talked-about one because of what it does,” says 
Reddy, who worked with Pfizer as a consultant. “It was tempting for Pfizer to take advantage of 
that and say, ‘We are a great pharmaceutical company doing innovative things.’ Instead, there 
was a lot of caution among senior Pfizer executives, who said, ‘We don’t want to place the 
company on the shoulders of Viagra.’.” 
“It so happens that soon after Viagra was launched, some old people died after taking Viagra. 
They didn’t die because of Viagra, but because of what they were doing after taking Viagra,” 
quipped Reddy in his presentation to the audience, drawing chuckles. “Pfizer management was 
very cautious about the spillover effects of even successful brands rubbing off on the parent 
brand. They say, ‘I can survive if Viagra goes away, but I might not survive a major hit on the 
Pfizer brand.’.” 
What are the lessons to be learnt from product failures, big and small? “Companies need to 
strike a balance among the competing needs – time to market; getting the product right; being on 
budget – to manage a brand effectively,” Reddy told Perspectives@SMU. “And even if you get it 
right, in industries with the possibility of catastrophic failures, avoid putting all your eggs (i.e. the 
entire company) in one basket (brand), even if that basket is very good.” 
 
